Priti S. Hegde, PhD, Director, CI Franchise Lead, Biomarkers Genentech Roche presents Blocking VEGF in addition to checkpoint inhibition in RCC at the 2016 annual International Kidney Cancer Symposium.
Priti S. Hegde, PhD, Director, CI Franchise Lead, Biomarkers Genentech Roche presents Blocking VEGF in addition to checkpoint inhibition in RCC at the 2016 annual International Kidney Cancer Symposium.